--- title: "Calidi Biotherapeutics (CLDI) news: reverse split and offering" url: "https://aibio.space/companies/calidi-biotherapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CLDI reverse split, offering and Nasdaq notice news: Calidi Biotherapeutics effects 1-for-16 reverse stock split. Calidi Biotherapeutics, Inc." --- CLDI Calidi Biotherapeutics, Inc. AMEX · United States # Calidi Biotherapeutics (CLDI) news CLDI reverse split, offering and Nasdaq notice news Listings · 2026-09-25 ## [Calidi Biotherapeutics receives NYSE American equity deficiency notice](https://aibio.space/news/calidi-biotherapeutics-receives-nyse-american-equity-deficiency-notice/) The notice, received September 21, 2026, says Calidi does not meet the exchange's stockholders' equity standard. The company must submit a compliance plan by October 21, 2026. ## Latest Calidi Biotherapeutics news 1. 2026-08-13 Legal [Calidi faces suits from two former finance staff and an investor's securities fraud claim](https://aibio.space/news/calidi-faces-suits-two-former-finance-staff-investors-securities-fraud/) Calidi, director and ex-CEO Allan Camaisa and ex-officer Ms. Pizarro are defendants in San Diego employment suits. Investor Yian Zeng's federal case against Calidi had a summary judgment hearing set for Aug 24, 2026. 2. 2026-07-27 Listings [Calidi Biotherapeutics effects 1-for-16 reverse stock split](https://aibio.space/news/calidi-biotherapeutics-effects-1-16-reverse-stock-split/) The split became effective July 30, 2026, and the common stock began trading split-adjusted on July 31 under the existing CLDI symbol. 3. 2026-07-10 Company Updates [Calidi Biotherapeutics signs new San Diego lease](https://aibio.space/news/calidi-biotherapeutics-signs-new-san-diego-lease/) The company signed a 44-month lease for Suite 120 at 5580 Morehouse Drive and agreed to terminate its existing lease, effective September 30, 2026. 4. 2026-06-23 Company Updates [Calidi Biotherapeutics appoints Corsee Sanders to board](https://aibio.space/news/calidi-biotherapeutics-appoints-corsee-sanders-board/) Dr. Corsee Sanders, a former Genentech/Roche and Celgene executive, joined the board as an independent director effective June 17, 2026. 5. 2026-05-29 Financings [Calidi Biotherapeutics amends warrant for up to 17,391,304 shares at $0.23, adds stockholder vote](https://aibio.space/news/calidi-biotherapeutics-amends-warrant-up-17-391-304-shares-0-23-adds/) Calidi Biotherapeutics replaced a May 6 warrant for up to 17,391,304 shares at $0.23 with one that cannot be exercised until stockholders approve it. The minimum vesting amount doubles to $1,000,000 and the vesting deadline moves to September 30, 2026. 6. 2026-05-14 Company Updates [Calidi reports first quarter 2026 results and CLD-401 progress](https://aibio.space/news/calidi-reports-first-quarter-2026-results-cld-401-progress/) Calidi reported a first quarter net loss of $4.4 million, a $1.0 million cut in general and administrative expenses and a CLD-401 IND goal of year end 2026. 7. 2025-10-31 Mergers [Calidi Biotherapeutics sells 75% Nova Cell stake for $6,000,000, mostly deferred and contingent](https://aibio.space/news/calidi-biotherapeutics-sells-75-percent-nova-cell-stake-6-000-000/) Nova Cell pays by cancelling a net $1,214,864 of debt Calidi owed it, plus $4,785,136 of deferred, contingent consideration. Nova Cell is no longer a subsidiary, and the company expects $0.5 million a year in expense cuts. 8. 2025-08-15 Financings [Calidi Biotherapeutics prices $6 million public offering of units at $2.00](https://aibio.space/news/calidi-biotherapeutics-prices-6-million-public-offering-units-2-00/) The offering combines common stock units and pre-funded warrant units, each with a Series I warrant exercisable at $2.00 for five years. 9. 2024-10-28 Listings [NYSE American files to remove Calidi Biotherapeutics warrants from listing](https://aibio.space/news/nyse-american-files-remove-calidi-biotherapeutics-warrants-listing/) The notice, dated October 28, 2024, covers the company's redeemable warrants with a $115.00 exercise price, not its common stock. ## Calidi Biotherapeutics at a glance - **Ticker**: CLDI - **Listing**: AMEX - **Country**: United States - **Cash, Jun 30, 2026**: $4.3 million ### Related companies - [Disc Medicine](https://aibio.space/companies/disc-medicine/) NASDAQ: IRON - [Q32 Bio](https://aibio.space/companies/q32-bio/) NASDAQ: QTTB - [Zura Bio](https://aibio.space/companies/zura-bio/) NASDAQ: ZURA - [NovelStem International](https://aibio.space/companies/novelstem-international/) OTC: NSTM - [Trevi Therapeutics](https://aibio.space/companies/trevi-therapeutics/) NASDAQ: TRVI - [Century Therapeutics](https://aibio.space/companies/century-therapeutics/) NASDAQ: IPSC - [Jasper Therapeutics](https://aibio.space/companies/jasper-therapeutics/) NASDAQ: JSPR - [Hemab Therapeutics Holdings](https://aibio.space/companies/hemab-therapeutics/) NASDAQ: COAG ### Also on AMEX - [NanoViricides](https://aibio.space/companies/nanoviricides/) NNVC - [AEON Biopharma](https://aibio.space/companies/aeon-biopharma/) AEON - [Nasus Pharma](https://aibio.space/companies/nasus-pharma/) NSRX - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) MTNB - [Protalix BioTherapeutics, Inc. (DE)](https://aibio.space/companies/protalix-biotherapeutics-de/) PLX - [IGC Pharma](https://aibio.space/companies/igc-pharma/) IGC ## Calidi Biotherapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$9.7 million](https://www.sec.gov/Archives/edgar/data/1855485/000149315226013242/) | [$8.9 million](https://www.sec.gov/Archives/edgar/data/1855485/000149315226013242/) | | Net income (loss) | [-$19.9 million](https://www.sec.gov/Archives/edgar/data/1855485/000149315226013242/) | [-$22.1 million](https://www.sec.gov/Archives/edgar/data/1855485/000149315226013242/) | | Cash from operations | [-$21.3 million](https://www.sec.gov/Archives/edgar/data/1855485/000149315226013242/) | [-$19.7 million](https://www.sec.gov/Archives/edgar/data/1855485/000149315226013242/) | | Cash and equivalents | [$5.8 million](https://www.sec.gov/Archives/edgar/data/1855485/000149315226037847/) | [$9.6 million](https://www.sec.gov/Archives/edgar/data/1855485/000164117225001810/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Calidi Biotherapeutics Did Calidi Biotherapeutics do a reverse stock split? Our latest story on this, dated Jul 27, 2026: "Calidi Biotherapeutics effects 1-for-16 reverse stock split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/calidi-biotherapeutics-effects-1-16-reverse-stock-split/). Has Calidi Biotherapeutics raised money recently? Our latest story on this, dated Aug 15, 2025: "Calidi Biotherapeutics prices $6 million public offering of units at $2.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/calidi-biotherapeutics-prices-6-million-public-offering-units-2-00/). Has Calidi Biotherapeutics received a Nasdaq deficiency notice? Our latest story on this, dated Sep 25, 2026: "Calidi Biotherapeutics receives NYSE American equity deficiency notice". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/calidi-biotherapeutics-receives-nyse-american-equity-deficiency-notice/). What is the ticker symbol of Calidi Biotherapeutics? Calidi Biotherapeutics, Inc. trades under the ticker CLDI on AMEX. Where is Calidi Biotherapeutics listed? Calidi Biotherapeutics, Inc. is listed on AMEX. What is the SEC CIK of Calidi Biotherapeutics? The SEC Central Index Key (CIK) for Calidi Biotherapeutics, Inc. is 1855485. Its filings are on SEC EDGAR. How many shares does Calidi Biotherapeutics have outstanding? 2,584,184 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Calidi Biotherapeutics listed under? Our directory records Calidi Biotherapeutics, Inc. under United States. What does Calidi Biotherapeutics do? Our directory classifies Calidi Biotherapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Calidi Biotherapeutics? The ISIN recorded for Calidi Biotherapeutics, Inc. is US3207035078. Does aibio.space cover Calidi Biotherapeutics? aibio.space lists Calidi Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Calidi Biotherapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Calidi Biotherapeutics profitable? Calidi Biotherapeutics, Inc. reported a net loss of $19.9 million for the fiscal year ended Dec 31, 2025, and used $21.3 million of cash in operations, per its annual report to the SEC. How much does Calidi Biotherapeutics spend on research and development? $9.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Calidi Biotherapeutics have? $4.3 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Calidi Biotherapeutics Members talk about Calidi Biotherapeutics (CLDI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Calidi Biotherapeutics, newest first. Each line links the filing it comes from. 1. 2026-09-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315226044381/ex99-1.htm) 2. 2026-08-13 Listings Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315226037840/ex99-1.htm) 3. 2026-07-31 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/form8-k.htm) 4. 2026-07-16 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315226033594/form8-k.htm) 5. 2026-06-18 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315226029374/form8-k.htm) 6. 2026-04-29 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315226019617/formdef14a.htm) 7. 2026-04-17 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315226017935/formpre14a.htm) 8. 2025-10-31 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315225020390/form8-k.htm) 9. 2025-08-15 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1855485/000164117225024489/forms-1.htm) 10. 2025-08-07 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000164117225022592/form8-k.htm) 11. 2025-07-25 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000164117225021039/ex99-1.htm) 12. 2025-07-11 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000164117225018808/form8-k.htm) 13. 2025-07-03 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1855485/000164117225017875/forms-1.htm) 14. 2025-05-23 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1855485/000164117225012252/formdef14a.htm) 15. 2025-05-12 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1855485/000164117225009711/formpre14a.htm) 16. 2025-05-02 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000164117225008365/form8-k.htm) 17. 2025-02-05 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315225004885/form424b5.htm) 18. 2025-01-28 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315225003916/ex99-1.htm) 19. 2025-01-10 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315225001711/form8-k.htm) 20. 2024-12-12 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315224049670/forms-1.htm) 21. 2024-11-29 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1855485/000149315224048189/form424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:CLDI on TradingView](https://www.tradingview.com/symbols/AMEX-CLDI/). ## SEC filings and registration - **SEC name**: Calidi Biotherapeutics, Inc. - **CIK**: 1855485 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: CLDI (NYSE), CLDWW (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 4475 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121 - **Phone**: 858-794-9600 - **Shares outstanding**: 2,584,184 as of 2026-08-10 (10-Q filed 2026-08-13) - **Former names**: Calidi Biotherapeutics, Inc.; First Light Acquisition Group, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1855485/000149315226044381/form8-k.htm) filed 2026-09-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1855485/000149315226043724/form8-k.htm) filed 2026-09-22 - [424B5](https://www.sec.gov/Archives/edgar/data/1855485/000149315226043156/form424b5.htm) filed 2026-09-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1855485/000149315226037847/form10-q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1855485/000149315226037840/form8-k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/form8-k.htm) filed 2026-07-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1855485/000149315226033594/form8-k.htm) filed 2026-07-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1855485/000149315226029710/form8-k.htm) filed 2026-06-23 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001855485), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Calidi Biotherapeutics, Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker CLDI, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Calidi Biotherapeutics, Inc. - **Ticker**: CLDI - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US3207035078 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-CLDI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/calidi-biotherapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Calidi Biotherapeutics (CLDI) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/calidi-biotherapeutics/